<a href="https://www.fiercebiotech.com/medtech/galmed-acquires-colospan-45m-deal-it-eyes-6b-gi-dx-market" hreflang="en">Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market</a>
Galmed Pharmaceuticals has acquired Colospan for $4.5 million to establish a gastrointestinal diagnostics platform targeting a $6 billion market, gaining access to Colospan's device technology and clinical programs. Meanwhile, CeQur raised $100 million to support the commercialization of its insulin patch, and ResMed completed a $340 million acquisition of Noctrix Health to enhance its sleep tech portfolio with a device for treating restless legs syndrome.
Galmed Pharmaceuticals' acquisition of Colospan for $4.5 million is a strategic move to enter the $6 billion gastrointestinal diagnostics market with a focus on developing their GI platform. Notably, Galmed gains access to Colospan's CG-100 intraluminal bypass device, which holds potential for FDA approval, highlighting an opportunity for investment in a promising medtech innovation aimed at reducing the need for diverting stomas and improving patient quality of life.